Cg Oncology, Common Stock Book Value Per Share
| CGON Stock | 34.75 0.65 1.91% |
CG Oncology, Common fundamentals help investors to digest information that contributes to CG Oncology,'s financial success or failures. It also enables traders to predict the movement of CGON Stock. The fundamental analysis module provides a way to measure CG Oncology,'s intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to CG Oncology, stock.
| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 42.67 | 44.80 | |
| Tangible Book Value Per Share | 42.67 | 44.80 |
CGON |
CG Oncology, Common Company Book Value Per Share Analysis
CG Oncology,'s Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
Current CG Oncology, Book Value Per Share | 7.95 X |
Most of CG Oncology,'s fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, CG Oncology, Common is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
CGON Book Value Per Share Driver Correlations
Understanding the fundamental principles of building solid financial models for CG Oncology, is extremely important. It helps to project a fair market value of CGON Stock properly, considering its historical fundamentals such as Book Value Per Share. Since CG Oncology,'s main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of CG Oncology,'s historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of CG Oncology,'s interrelated accounts and indicators.
Click cells to compare fundamentals
CGON Book Value Per Share Historical Pattern
Today, most investors in CG Oncology, Stock are looking for potential investment opportunities by analyzing not only static indicators but also various CG Oncology,'s growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's book value per share growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of CG Oncology, book value per share as a starting point in their analysis.
CG Oncology, Book Value Per Share |
| Timeline |
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
| Competition |
In accordance with the recently published financial statements, the book value per share of CG Oncology, Common is about 7.948 times. This is 567.53% lower than that of the Biotechnology sector and 103.2% lower than that of the Health Care industry. The book value per share for all United States stocks is 99.59% higher than that of the company.
CGON Book Value Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CG Oncology,'s direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of CG Oncology, could also be used in its relative valuation, which is a method of valuing CG Oncology, by comparing valuation metrics of similar companies.CG Oncology, is currently under evaluation in book value per share category among its peers.
CGON Fundamentals
| Return On Equity | -0.2 | ||||
| Return On Asset | -0.16 | ||||
| Operating Margin | (658.02) % | ||||
| Current Valuation | 1.77 B | ||||
| Shares Outstanding | 67.63 M | ||||
| Shares Owned By Insiders | 6.94 % | ||||
| Shares Owned By Institutions | 92.27 % | ||||
| Number Of Shares Shorted | 5.4 M | ||||
| Price To Book | 4.30 X | ||||
| Price To Sales | 3,372 X | ||||
| Revenue | 204 K | ||||
| EBITDA | (55.43 M) | ||||
| Net Income | (48.61 M) | ||||
| Total Debt | 461 K | ||||
| Book Value Per Share | 7.95 X | ||||
| Cash Flow From Operations | (45.68 M) | ||||
| Short Ratio | 13.33 X | ||||
| Earnings Per Share | (15.87) X | ||||
| Target Price | 66.63 | ||||
| Number Of Employees | 61 | ||||
| Market Capitalization | 2.31 B | ||||
| Total Asset | 199.3 M | ||||
| Retained Earnings | (129.94 M) | ||||
| Working Capital | 179.87 M | ||||
| Net Asset | 199.3 M |
About CG Oncology, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CG Oncology, Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CG Oncology, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CG Oncology, Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with CG Oncology,
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CG Oncology, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CG Oncology, will appreciate offsetting losses from the drop in the long position's value.Moving against CGON Stock
| 0.45 | BMY | Bristol Myers Squibb Sell-off Trend | PairCorr |
| 0.43 | ESPR | Esperion Therapeutics Buyout Trend | PairCorr |
| 0.39 | VTRS | Viatris | PairCorr |
| 0.32 | BFRIW | Biofrontera Warrants | PairCorr |
The ability to find closely correlated positions to CG Oncology, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CG Oncology, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CG Oncology, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CG Oncology, Common to buy it.
The correlation of CG Oncology, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CG Oncology, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CG Oncology, Common moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CG Oncology, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out CG Oncology, Piotroski F Score and CG Oncology, Altman Z Score analysis. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CG Oncology,. If investors know CGON will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CG Oncology, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (15.87) | Revenue Per Share 0.015 | Quarterly Revenue Growth 3.778 | Return On Assets (0.16) | Return On Equity (0.20) |
The market value of CG Oncology, Common is measured differently than its book value, which is the value of CGON that is recorded on the company's balance sheet. Investors also form their own opinion of CG Oncology,'s value that differs from its market value or its book value, called intrinsic value, which is CG Oncology,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CG Oncology,'s market value can be influenced by many factors that don't directly affect CG Oncology,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CG Oncology,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if CG Oncology, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CG Oncology,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.